European Union regulators can either clear the deal with or without ... The $16.5 billion deal, announced in February, ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...

Wegovy is expected to cost patients €270 ... and shortages have been reported across the European Union since 2022. Related Denmark's Novo Nordisk invests €2.1 billion in France But despite ...

European shares ended lower on Wednesday, following a broad rally earlier in the session, hurt by a drop in utilities shares ...

Rybelsus is an oral form of semaglutide, the active ingredient in the company's blockbuster Ozempic and Wegovy diabetes ... in both the U.S. and European Union around the turn of the year.

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that focuses on diabetes care and obesity treatment. The company is one of the world’s leading producers of insulin and other ...

Climate scientists working at the European Union's Copernicus Climate Change Service have announced that 2024 is "virtually certain" to be the warmest year on record. According to its ERA5 dataset ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union antitrust officials are asking rival pharmaceuticals ... which should help increase production of the ...